Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Trial Profile

Randomized, Multicenter, Phase III, Open-Label Study of Alectinib Versus Pemetrexed or Docetaxel in Anaplastic Lymphoma Kinase-Positive Advanced Non Small Cell Lung Cancer Patients Previously Treated With Platinum-Based Chemotherapy and Crizotinib

Active, no longer recruiting
Phase of Trial: Phase III

Latest Information Update: 22 Sep 2017

At a glance

  • Drugs Alectinib (Primary) ; Docetaxel; Pemetrexed
  • Indications Non-small cell lung cancer
  • Focus Registrational; Therapeutic Use
  • Acronyms ALUR
  • Sponsors Roche
  • Most Recent Events

    • 12 Sep 2017 Results of CNS efficacy of alectinib presented at the 42nd European Society for Medical Oncology Congress
    • 06 Sep 2017 Results from this trial will be presented at the European Society for Medical Oncology (ESMO) 2017 Congress, according to a Roche media release.
    • 06 Sep 2017 Results published in a Roche media release.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top